Concord Biotech Limited announced the FDA approval of its ANDA for Mycophenolate Sodium Oral Suspension, providing a crucial oral bioequivalent to Mycophenolate Sodium USP. This authorization enables the company to expand its pharmaceutical portfolio, enhancing its competitive position in the immunosuppressant market by offering a reliable generic option for patients requiring oral therapy.